Highest-materiality recent filing
Federal Circuit affirms Exelixis patents; generic competitor blocked until Jan 15, 2030
Court of Appeals affirmed validity of U.S. Patent Nos. 11,091,439, 11,091,440, 11,098,015.
Exelixis Q2 2026 revenue $628.7M, GAAP EPS $0.82, non-GAAP EPS $0.91
Total revenues $628.7M, up 11% YoY; cabozantinib U.S. net product revenues $573.0M.
Exelixis Q1 revenue $610.8M, GAAP EPS $0.79; announces $750M buyback
Total revenues $610.8M (+10% YoY); cabozantinib U.S. net product revenue $555.0M.
Exelixis Q4 revenue $599M, diluted EPS $0.88; cabozantinib franchise up 17% in FY2025
Q4 2025 total revenue $598.7M vs $566.8M YoY; GAAP diluted EPS $0.88 vs $0.48.
Exelixis Q3 revenues $597.8M, EPS $0.69; announces $750M stock buyback by 2026
Total revenues $597.8M (+10.8% YoY); cabozantinib US net product rev $542.9M (+13.5% YoY).
Exelixis appoints Dana Aftab as EVP R&D; Amy Peterson departs as CMO
Dana Aftab, Ph.D., promoted to EVP of R&D effective August 29, 2025; previously EVP Discovery & CSO.
Exelixis Q2 2025: total rev $568M, GAAP EPS $0.65; CABOMETYX NET launch, positive STELLAR-303
Total revenues $568.3M; product revenues $520.0M (+19% YoY); collaboration rev $48.2M (down $151M due to prior-year Ipsen milestone).
Exelixis Q1 2025: Revenue $555.4M, GAAP EPS $0.55; raises FY2025 guidance by $100M
Total revenues $555.4M (up 31% YoY); Cabozantinib U.S. net product revenues $513.3M (up 36% YoY).
Exelixis approves special PSU awards for all employees with $60 stock price performance goal
CEO Michael Morrissey receives 589,719 shares of PSU; other NEOs receive between 132,819 and 170,009 shares.
Exelixis board authorizes additional $500M stock repurchase program
New $500M authorization to be completed by Dec 31, 2025; current $500M program expected to finish in Q2 2025.
Exelixis Q4 2024 rev $567M, GAAP EPS $0.48; FY2024 rev $2.17B, EPS $1.76
Total revenues $566.8M for Q4 2024, up 18% YoY; FY2024 total rev $2.17B, up 18% YoY.
Exelixis Q3 revenue $539.5M, EPS $0.40; raises FY 2024 guidance
Q3 net product revenue $478.1M (cabozantinib franchise) vs $426.5M YoY, +12%.
Exelixis enters clinical collaboration with Merck for zanzalintinib combo trials in HNSCC and RCC
Collaboration covers zanzalintinib + KEYTRUDA in phase 3 HNSCC trial (STELLAR-305) and zanzalintinib + WELIREG in RCC phase 1/2 and two phase 3 trials.
Exelixis wins patent case against MSN; generic launch blocked until Jan 2030
Delaware court rejected MSN's invalidity challenges to three cabozantinib patents (11,091,439, 11,091,440, 11,098,015), all expiring Jan 15, 2030.
Exelixis Q2 revenue $637M, GAAP EPS $0.77; $500M buyback, FDA accepts cabozantinib sNDA
Total revenues $637.2M vs $469.8M YoY; cabozantinib U.S. net product revenues $437.6M.
Exelixis settles CABOMETYX patent litigation; Cipla generic launch from Jan 1, 2031
Settlement with Cipla resolves two Hatch-Waxman patent suits over CABOMETYX (cabozantinib).
Exelixis sues Cipla over generic Cabometyx patents covering 20mg, 40mg strengths
Cipla amended its ANDA to seek approval for 20mg and 40mg generic cabozantinib, adding Paragraph IV certifications.
Exelixis Q1: revenue $425M, GAAP EPS $0.12, non-GAAP $0.17, restructuring $32.8M
Total revenues $425.2M, up 4% YoY from $408.8M; cabozantinib U.S. net product revenues $378.5M, up from $363.4M.
Exelixis Q4 2023 revenue $479.7M, GAAP EPS $0.27, non-GAAP $0.33; FY revenue $1.83B
Total Q4 revenues $479.7M (up from $423.9M YoY); cabozantinib net product revenues $429.3M.
Exelixis cuts 13% of workforce, authorizes $450M share repurchase, adds two directors
Restructuring plan: workforce reduction of ~175 employees (13% of total headcount); total charges estimated at ~$25M, recognized in Q1 2024.
Exelixis Q3 revenue up 15% to $471.9M but GAAP net income drops to $1.0M from $73.2M
Q3 total revenues $471.9M (up 14.6% YoY); net product rev $426.5M (up 16.4% YoY).
Exelixis CMO Vicki Goodman departs effective August 23, 2023; entitled to severance benefits
Vicki L. Goodman, EVP Product Development & Medical Affairs and CMO, concludes service effective August 23, 2023.
Exelixis Q2 revenue $469.8M, GAAP EPS $0.25; CABOMETYX drives growth
Total revenues $469.8M (+12% YoY); net product revenues $409.6M (+18% YoY).
Exelixis settles patent litigation with Teva; generic CABOMETYX license begins Jan 1, 2031
Settlement and License Agreement with Teva resolves patent litigation over generic CABOMETYX (cabozantinib).
Exelixis Q1 revenue up 15% to $408.8M, but GAAP EPS falls to $0.12 on higher R&D spend
Total revenues $408.8M (+15% YoY); Cabozantinib franchise net product revenues $363.4M (+17% YoY).
Exelixis director Lance Willsey resigns; Board adds Farallon nominee, ends proxy fight
Lance Willsey, M.D. resigned from Exelixis board effective May 7, 2023; resignation relates to personal matter from over a decade ago.
Exelixis board refresh: two directors not standing; new nominees after failed Farallon settlement
Carl Feldbaum and Vincent Marchesi will not stand for re-election at 2023 Annual Meeting.
Exelixis files patent infringement suit against Cipla over generic CABOMETYX
Filed complaint in Delaware district court against Cipla for ANDA seeking approval of generic cabozantinib tablets (20/40/60 mg).
Exelixis authorizes $550M share repurchase program through end of 2023
Board authorized up to $550M of common stock repurchases before end of 2023.
Exelixis posts Q4 net loss $30.2M; cabozantinib franchise revenue $1.4B for FY2022
Q4 total revenues $423.9M, down 6% from $451.1M a year ago; cabozantinib U.S. net product revenues $377.4M.
Exelixis Q3 revenue $411.7M; cabozantinib franchise up 39% YoY; GAAP EPS $0.23
Total revenues $411.7M (up 25% YoY); cabozantinib net product revenue $366.5M (+39% YoY).
Exelixis files second patent infringement suit against Teva over generic CABOMETYX
Exelixis filed complaint against Teva for infringing U.S. Patent No. 11,298,349 covering CABOMETYX (cabozantinib) tablets.
Exelixis Q2 2022 revenue $419.4M, cabozantinib net product revenue $347M, GAAP EPS $0.22
Total revenues $419.4M, up from $385.2M in Q2 2021; cabozantinib franchise net product revenue $347.0M, up 22% YoY.
Exelixis sues MSN for generic CABOMETYX, asserting new patent expiring 2032
Filed patent infringement suit against MSN for generic CABOMETYX, asserting U.S. Patent No. 11,298,349 (expires Feb 10, 2032).
Exelixis Q1 2022 revenue $356M, EPS $0.21; cabozantinib franchise $310.3M
Total revenues $356.0M vs $270.2M YoY; net product revenues $310.3M vs $227.2M, driven by higher cabozantinib volume.
Exelixis files new patent infringement suit against MSN over generic CABOMETYX
Filed complaint in Delaware asserting infringement of three new patents (11,091,439; 11,091,440; 11,098,015) related to cabozantinib.
On March 27, 2024, Jacqueline Wright notified Exelixis, Inc. (“the Company”) of her decision not to stand for re-election to the Board of Directors of the Company
the Board increased the size of the Board to 13 members and appointed Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. to the Board to fill the newly created vacancies, effective immediately.
the Board increased the size of the Board to 13 members and appointed Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. to the Board to fill the newly created vacancies, effective immediately.
Alan M. Garber, M.D., Ph.D., informed the Company that he has decided not to stand for re-election to the Board when his term expires at the 2024 annual meeting of stockholders.
Vicki L. Goodman, M.D., concluded her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of the Company, effective as of August 23, 2023.
Effective August 23, 2023, Vicki L. Goodman, M.D., will conclude her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of Exelixis, Inc.
On May 7, 2023, the Board of Directors (the “Board”) of Exelixis, Inc. (the “Company”) announced that Dr. Lance Willsey was resigning from the Board effective immediately
Peter Lamb, Ph.D., currently, Executive Vice President, Scientific Strategy and Chief Scientific Officer of Exelixis, Inc. (“Exelixis” or the “Company”), will transition into a new role as Executive Vice President, Scientific Strategy, effective as of today.
Dana T. Aftab, Ph.D., will become the Company’s next Chief Scientific Officer and will also serve as Executive Vice President, Discovery and Translational Research.
On April 11, 2022, Charles Cohen, Ph.D. notified Exelixis, Inc. (“Exelixis”) of his decision not to stand for re-election to the Board of Directors of Exelixis (the “Board”) at the 2022 annual meeting of stockholders of Exelixis (the “Annual Meeting”) and resign from the Board effective as of the Annual Meeting.
the Board increased the size of the Board to 12 members and appointed Jacky Wright to the Board to fill the newly created vacancy.
Max materiality 0.85 · Median 0.65 · Most common event earnings